Sanofi-aventis announced that it has signed a global license agreement with CureDM Group on a novel human peptide, Pancreate™, which could restore a patients’ ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes. Pancreate™ is a bioactive peptide sequence of a naturally occurring human protein that has been shown in preclinical studies to stimulate the growth of new insulin producing islets in the pancreas, resulting in restoration of normal metabolic function and glucose control in the blood. The commencement of Phase I studies is planned for later this year.
Sanofi-aventis will have exclusive worldwide license to develop, manufacture and commercialize Pancreate™ and related compounds. CureDM will receive an upfront payment, as well as development, regulatory and commercial milestone payments. All such payments could reach a total of US$ 335 million. CureDM will also receive tiered royalties on worldwide product sales.
My son and grandson are type 1 diabetics. Hearing the news of your development of Pancreate we are obvilously extremely interested in being involved in any program Sanofi-aventis has to offer. Please be so kind to advise if this is possible, Thankyou Charles Flynn